Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methacholine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | GALR3 | O60755 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.95 |
| ▸ | TSHR | P16473 | 3/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.95 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.95 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methacholine SCHEMBL24465400 | 0.98 | CHRM1 (1.00) | MAPTSMN1; SMN2GALR3BLMCHRM1 | |
| Methacholine SCHEMBL69103 | 0.98 | CHRM1 (1.00) | MAPTSMN1; SMN2GALR3BLMCHRM1 | |
| Methacholine SCHEMBL424740 | 0.95 | CHRM1 (0.95) | MAPTSMN1; SMN2GALR3BLMCHRM1 | |
| Methacholine SCHEMBL1256548 | 0.95 | CHRM1 (0.95) | MAPTSMN1; SMN2GALR3BLMCHRM1 | |
| Methacholine SCHEMBL1539028 | 0.95 | CHRM1 (0.95) | MAPTSMN1; SMN2GALR3BLMCHRM1 | |
| Methacholine SCHEMBL16340808 | 0.95 | CHRM1 (0.95) | MAPTSMN1; SMN2GALR3BLMCHRM1 | |
| Methacholine SCHEMBL2349212 | 0.95 | CHRM1 (0.95) | MAPTSMN1; SMN2GALR3BLMCHRM1 | |
| SCHEMBL12743772 | 0.88 | MAPT (0.79) | MAPTSMN1; SMN2GALR3BLMCHRM1 | |
| Methacholine SCHEMBL1536636 | 0.83 | TSHR (0.72) | MAPTSMN1; SMN2GALR3BLMCHRM1 | |
| Methacholine SCHEMBL584417 | 0.82 | CHRM1 (0.70) | MAPTSMN1; SMN2GALR3BLMCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12707 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260130896-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739312-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS Therapeutics LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-20260083698-A1 | Synergistic Stimulation of Mucociliary Clearance to Treat Mucus Obstruction in Cystic Fibrosis and Other Muco-Obstructive Disorders | UNIV LELAND STANFORD JUNIOR (US) | 2026-03-26 | — | — | US | claimed |
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | claimed |
| WO-2025244639-A1 | METHODS FOR TREATING LUNG DISEASES AND DISORDERS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| US-12433902-B2 | Liposomal formulations for inhibiting SARS-CoV-2 replication and reducing lung inflammation | VGSK TECHNOLOGIES, INC. (US) | 2025-10-07 | — | — | US | claimed |
| US-12396661-B2 | Devices for integrated indirect sweat stimulation and sensing | UNIVERSITY OF CINCINNATI (US) | 2025-08-26 | — | — | US | claimed |
| US-5010056-A | Growth disorders | PIERREL SPA (IT) | 1991-04-23 | — | — | US | claimed |
| WO-1990010453-A1 | USE OF INTERCELLULAR ADHESION MOLECULES, AND THEIR BINDING LIGANDS IN THE TREATMENT OF ASTHMA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1990-09-20 | — | — | WO | claimed |
| EP-0387701-A1 | Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma | Boehringer Ingelheim Pharmaceuticals Inc. (US) | 1990-09-19 | — | — | EP | claimed |
| EP-0301392-A1 | Pharmaceutical composition for intranasal administration comprising GH - Releasing hormone, a cholinergic agonist and in case a bile salt | Pierrel S.p.A. (IT) | 1989-02-01 | — | — | EP | claimed |
| EP-0257956-A2 | Device and dispersion for intrapulmonary delivery of polypeptide growth factors and cytokines | GENENTECH, INC. (US) | 1988-03-02 | — | — | EP | claimed |
| US-4665069-A | PARASYMPATHOMIMETIC AGENT | ROSENBERG BARNETT | 1987-05-12 | — | — | US | claimed |
| US-4661509-A | ENZYME INHIBITORS | GORDON ARNOLD Z | 1987-04-28 | — | — | US | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4474751-A | SUSTAINED RELEASE USING AN ALKYLENEDIAMINE-MODIFIED ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |
| US-4059686-A | SODIUM POLYACRYLATE | NIPPON KAYAKU KABUSHIKI KAISHA (JA) | 1977-11-22 | — | — | US | claimed |